STERIS (NYSE:STE) Updates FY 2025 Earnings Guidance

STERIS (NYSE:STE - Get Free Report) updated its FY 2025 earnings guidance on Wednesday. The company provided EPS guidance of 9.050-9.150 for the period, compared to the consensus EPS estimate of 9.060. The company issued revenue guidance of $5.4 billion-$5.4 billion, compared to the consensus revenue estimate of $5.5 billion.

Analyst Ratings Changes

STE has been the topic of a number of analyst reports. JMP Securities reaffirmed a "market outperform" rating and issued a $265.00 price objective on shares of STERIS in a report on Thursday. StockNews.com downgraded STERIS from a "strong-buy" rating to a "buy" rating in a research report on Tuesday, October 29th. Stephens reaffirmed an "overweight" rating and set a $240.00 price target on shares of STERIS in a research note on Thursday. Needham & Company LLC reaffirmed a "hold" rating on shares of STERIS in a research report on Friday, November 8th. Finally, Piper Sandler upped their price target on shares of STERIS from $260.00 to $265.00 and gave the stock an "overweight" rating in a research report on Monday, February 3rd. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, STERIS currently has a consensus rating of "Moderate Buy" and a consensus target price of $258.75.

STERIS Price Performance

NYSE:STE traded down $2.31 during mid-day trading on Friday, hitting $223.13. The company's stock had a trading volume of 682,890 shares, compared to its average volume of 513,142. The company has a current ratio of 2.13, a quick ratio of 1.55 and a debt-to-equity ratio of 0.32. The company has a market capitalization of $22.03 billion, a price-to-earnings ratio of 47.37 and a beta of 0.84. STERIS has a fifty-two week low of $197.82 and a fifty-two week high of $248.24. The stock has a fifty day moving average of $212.57 and a 200-day moving average of $224.56.

STERIS (NYSE:STE - Get Free Report) last announced its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $2.32 EPS for the quarter, missing analysts' consensus estimates of $2.33 by ($0.01). STERIS had a return on equity of 13.91% and a net margin of 8.66%. As a group, equities analysts forecast that STERIS will post 9.08 EPS for the current fiscal year.

STERIS Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 21st. Shareholders of record on Thursday, February 20th will be paid a $0.57 dividend. The ex-dividend date is Thursday, February 20th. This represents a $2.28 annualized dividend and a yield of 1.02%. STERIS's dividend payout ratio is 48.41%.

Insider Buying and Selling at STERIS

In other news, SVP Cary L. Majors sold 1,682 shares of STERIS stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $217.32, for a total value of $365,532.24. Following the completion of the transaction, the senior vice president now directly owns 11,372 shares of the company's stock, valued at approximately $2,471,363.04. This trade represents a 12.88 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 1.14% of the company's stock.

STERIS Company Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.